Cell Impact publishes information document regarding the rights issue

Cell Impact AB has launched a rights issue approved by the board and an extraordinary general meeting to offer one new share per existing share at SEK 0.13, with a record date of 4 February 2026; the subscription period runs 6–20 February and subscription rights are expected to trade 6–17 February on Nasdaq First North. If fully subscribed the raise would deliver approximately SEK 38.3 million before costs, but the issue is only covered to ~60% by subscription and guarantee commitments, implying potential dilution risk and execution uncertainty. The company — a listed supplier of flow plates with patented Cell Impact Forming™ technology for fuel cells and electrolyzers — has registered an information document with the Swedish Financial Supervisory Authority and engaged Stockholm Corporate Finance AB (financial adviser) and Aqurat Fondkommission AB (issuing agent).

Analysis

Market structure: The rights issue (1-for-1 at SEK 0.13) implies up to ~SEK 38.3m and will double the share count if fully subscribed — an immediate ~50% theoretical dilution to existing free float. Direct winners are guarantors/underwriters and shareholders who exercise rights; losers are non-participating holders and short-term liquidity providers because issuance pressure typically depresses price by 20–40% in small-cap Swedish listings over 1–4 weeks. For competitors (NEL.OL, PLUG, BLDP) the event lowers Cell Impact’s near-term cash-constrained credibility, preserving incumbents’ pricing power in the next 6–18 months.

Risk assessment: Tail risks include a failed subscription (coverage only ~60% committed) forcing emergency bridge financing or deep secondary at lower prices — a >50% equity haircut scenario within 30–90 days. Operational risk: inability to convert Cell Impact Forming™ into scalable contracts would make the SEK 38m runway burn through in 6–12 months without revenue. Key hidden dependency: guarantee counterparty identity and conditionality (if insiders guarantee with short lock-ups, selling pressure can spike post-registration). Catalysts: subscription outcome (announce ~24 Feb), pilot contract wins, or regulatory changes for hydrogen/green subsidies.

Trade implications: Short-term (days–weeks) expect downward pressure through rights trading window (6–20 Feb) — arbitrage: short shares vs buy rights if rights price < fair dilution-adjusted value. Medium-term (3–12 months) prefer long exposure to liquid electrolyzer/hydrogen names NEL.OL and PLUG vs small-cap Cell Impact; options plays include buying 3–6 month puts on Cell Impact or put spreads if implied vols present. Reallocate 2–4% portfolio from illiquid First North small-caps into larger traded hydrogen/renewable equities and selective ETFs.

Contrarian angles: Market likely underweights IP leverage — Cell Impact’s patented forming tech could win OEM contracts and create >3x upside if it secures 1–2 large OEM agreements within 12–24 months, making a small asymmetric call attractive. Reaction may be overdone if rights fully subscribe and no large-cap selling follows; cap raise can be a reset. Historical parallels: early-stage technology raises often compress price then retrace after execution — a disciplined, size-limited (1–2% NAV) speculative long can capture that optionality while limiting dilution risk.

Key Decisions for Investors

• If liquid, establish a tactical short (1–2% NAV) in Cell Impact shares during 6–20 Feb to capture expected rights-induced pressure; cover or reassess within 10 trading days after the 24 Feb outcome; set stop-loss at 15% adverse move.
• Execute a relative-value pair: go long NEL.OL (1–2% NAV) and short Cell Impact (equal dollar) for a 3–9 month horizon — thesis: incumbent electrolyzer exposure benefits while small-cap execution/dilution risk penalises Cell Impact.
• If you hold Cell Impact stock, buy 3–6 month protective puts (or put spread) sized to cover 50–100% of position notional; target breakeven if shares fall >30% from pre-rights level.
• Place a small asymmetric long (0.5–1% NAV) in Cell Impact conditional on buying rights during 6–17 Feb only if the market price of a right < SEK 0.06 (implies cheap optional upside vs SEK 0.13 subscription price) and maintain position no longer than 12–24 months unless OEM contract announced.
• Reduce total small-cap renewable supplier exposure by 2–4% and redeploy into liquid hydrogen/renewable names (e.g., NEL.OL, PLUG) over next 30 days; reweight if guarantee coverage reported <70% on 24 Feb (increase defensive hedges).